Robert Y. Kim, MDCHIEF MEDICAL OFFICER
Dr. Kim joined Apellis as Chief Medical Officer in August 2016. He received his undergraduate and MD degrees from Brown University. Dr. Kim completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology at the National Eye Institute, and retina fellowship training at Moorfields Eye Hospital in London before joining the faculty at UCSF. Prior to transitioning to industry, Bob completed a MBA at University of California, Berkeley’s Haas School of Business. Bob started out in the life science industry in medical devices, first at Zeiss Humphrey Systems (now Carl Zeiss Meditec) working on the Stratus OCT and then at the German venture capital firm, Earlybird, where he supported medical device portfolio companies. He then transitioned to drug development at Genentech, where he managed the Lucentis Phase 3 clinical program through to its first approval in wet age related macular degeneration (AMD), GSK where, as VP of Clinical Ophthalmology, he helped build an early stage clinical pipeline, Novartis Institutes for Biomedical Research and the Novartis Alcon division, where he was vice president and Head of Pharmaceutical Product Development and, most recently, at retina startup, Vision Medicines, where he was Chief Medical Officer and Head of R&D. He is currently Associate Clinical Professor of Ophthalmology at UCSF, where he continues to see patients.